Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the addition of a platinum resistance AI signature to ...

IRVING, Texas, April 7, 2025 /PRNewswire/ — Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company has closed a ...

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...

Contact [email protected] to schedule meetings. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, following the FDA’s approval of its multi-cancer companion diagnostic test last ...

IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences (CAI) ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced ...

Biotechnology and precision medicine company Caris Life Sciences announced it raised $168 million in growth capital funding. Caris Life Sciences has now raised $1.86 billion in capital since 2018.

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...

Caris Life Sciences Inc. CAI shares are up during Friday’s premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company’s Achieve 1 study ...

At the USCAP conference, Caris Life Sciences will present a total of five studies developed in collaboration with more than 20 specialized cancer centers. The research focus will be on the molecular ...

On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq’s opening bell in New York, marking the company’s awaited initial public offering. Founded in 2008 by David ...

New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current methods to predict recurrence risk in ...